ACADIA Pharmaceuticals Inc. Third Quarter 2004 Earnings Conference Call.SAN DIEGO -- ACADIA Acadia (əkā`dēə), Fr. Acadie, region and former French colony, E Canada, encompassing modern Nova Scotia but also New Brunswick, Prince Edward Island, and coastal areas of E Maine. After an abortive 1604 settlement of St. Pharmaceuticals Inc. (Nasdaq:ACAD ACAD Academy ACAD Academic ACAD AutoCAD (design/drafting development software by Autodesk) ACAD Acadia National Park (US National Park Service) ACAD Atherosclerotic Coronary Artery Disease ), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders Nervous system disorders A satisfactory classification of diseases of the nervous system should include not only the type of reaction (congenital malformation, infection, trauma, neoplasm, vascular diseases, and degenerative, metabolic, toxic, or deficiency , today announced that it will report third quarter 2004 financial results on Wednesday, November 10, 2004, after the U.S. financial markets close. ACADIA will host a conference call and webcast on Wednesday, November 10, 2004 at 4:30 p.m. EST to discuss financial results for the third quarter ended September 30, 2004. Uli Hacksell, Ph.D., ACADIA's Chief Executive Officer, will also provide an update on the Company's progress. The conference call may be accessed by dialing 800-901-5247 for participants from the United States or Canada and 617-786-4501 for international callers (reference participant passcode 92945056). The conference call will also be webcast live on ACADIA's website at www.acadia-pharm.com, under the investor relations Investor relations The process by which the corporation communicates with its investors. section, and will be archived there until November 24, 2004. About ACADIA Pharmaceuticals ACADIA Pharmaceuticals is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders. ACADIA currently has five drug programs in clinical and preclinical development directed at large unmet medical needs and major commercial markets, including Parkinson's disease Parkinson's disease or Parkinsonism, degenerative brain disorder first described by the English surgeon James Parkinson in 1817. When there is no known cause, the disease usually appears after age 40 and is referred to as Parkinson's disease. , schizophrenia, chronic pain, and glaucoma. Using its proprietary drug discovery platform, ACADIA has discovered all of the drug candidates in its product pipeline. ACADIA's corporate headquarters and biology research facilities are located in San Diego, California “San Diego” redirects here. For other uses, see San Diego (disambiguation). San Diego is a coastal Southern California city located in the southwestern corner of the continental United States. As of 2006, the city has a population of 1,256,951. and its chemistry research facilities are located near Copenhagen, Denmark. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion